The constitutive androstane receptor is a novel therapeutic target facilitating cyclophosphamide-based treatment of hematopoietic malignancies
Duan Wang(University of Maryland, Baltimore), Hongbing Wang(University of Maryland, Baltimore), Ronald B. Gartenhaus(University of Maryland, Baltimore), Linhao Li(Beihang University), Stephen Ferguson(National Institute of Environmental Health Sciences), Hui Yang(Huazhong Agricultural University), Maria R. Baer(University of Maryland, Baltimore)
Cited by 44
Related Papers
Gilteritinib or Chemotherapy for Relapsed or Refractory <i>FLT3</i> -Mutated AML
|New England Journal of Medicine|2019|1.3k
KTE-X19 for relapsed or refractory adult B-cell acute lymphoblastic leukaemia: phase 2 results of the single-arm, open-label, multicentre ZUMA-3 study
|The Lancet|2021|795
<i>IDH1</i> and <i>IDH2</i> Gene Mutations Identify Novel Molecular Subsets Within De Novo Cytogenetically Normal Acute Myeloid Leukemia: A Cancer and Leukemia Group B Study
|Journal of Clinical Oncology|2010|764